Bone morphogenetic protein-2 levels are elevated in the patients with gastric cancer and correlate with disease progression

Yong Park, Myoung Hee Kang, Hee Yeon Seo, Joong Min Park, Chul Won Choi, Yeul Hong Kim, In Sun Kim, Jun Suk Kim, Sang Cheul Oh

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Bone morphogenetic protein-2 (BMP-2) was reported to enhance migration, invasion, and metastasis at the various types of cancer cells. The purpose of this study is to identify the role of BMP-2 in progression of gastric cancer. Forty-four patients with operable gastric cancer were enrolled. Also, twenty healthy volunteers were enrolled as control group. All patients received gastrectomy with D2 lymphadenectomy, and surgical staging was performed. Whole blood was obtained preoperatively in all patients, and serum BMP-2 levels were quantified by commercially available ELISA kit. Immunohistochemical stain for BMP-2 in all gastric cancer tissues was performed using tissue microarray. All patients showed increased serum BMP-2 levels compared with control group, when upper normal limit was defined as the mean of control serum level + 2 × standard deviation. The mean serum BMP-2 level of lymph node positive group was significantly elevated than that of lymph node-negative group (382.7 pg/ml, 95% CI 341.99-423.4 pg/ml vs 211.69 pg/ml, 95% CI 191.09-232.29 pg/ml, P < 0.001). The serum BMP-2 was strongly correlated with the depth of invasion (T stage) and the extent of regional lymph node involvement (N stage) (r = 0.662, P < 0.001 and r = 0.831, P < 0.001, respectively). Moreover, the serum BMP-2 was correlated with the grade of tumor histology(r = 0.421, P = 0.008). Immunohistochemical stain showed the specific expression of BMP-2 in cancer cells compared with normal gastric mucosa. In conclusion, serum BMP-2 is associated with progression from early localized gastric cancer to locally advanced gastric cancer.

Original languageEnglish
Pages (from-to)1192-1199
Number of pages8
JournalMedical Oncology
Volume27
Issue number4
DOIs
Publication statusPublished - 2010 Dec 1

Fingerprint

Bone Morphogenetic Protein 2
Stomach Neoplasms
Disease Progression
Blood Proteins
Lymph Nodes
Coloring Agents
Neoplasms
Control Groups
Gastrectomy
Gastric Mucosa
Lymph Node Excision
Histology
Healthy Volunteers
Enzyme-Linked Immunosorbent Assay
Neoplasm Metastasis

Keywords

  • Bone morphogenetic protein 2
  • Enzyme-linked immunosorbent assay
  • Immunohistochemistry
  • Neoplasm invasiveness
  • Stomach neoplasm
  • Tumorigenesis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology

Cite this

Bone morphogenetic protein-2 levels are elevated in the patients with gastric cancer and correlate with disease progression. / Park, Yong; Kang, Myoung Hee; Seo, Hee Yeon; Park, Joong Min; Choi, Chul Won; Kim, Yeul Hong; Kim, In Sun; Kim, Jun Suk; Oh, Sang Cheul.

In: Medical Oncology, Vol. 27, No. 4, 01.12.2010, p. 1192-1199.

Research output: Contribution to journalArticle

@article{bba43590212c43b189068a8bf90462b8,
title = "Bone morphogenetic protein-2 levels are elevated in the patients with gastric cancer and correlate with disease progression",
abstract = "Bone morphogenetic protein-2 (BMP-2) was reported to enhance migration, invasion, and metastasis at the various types of cancer cells. The purpose of this study is to identify the role of BMP-2 in progression of gastric cancer. Forty-four patients with operable gastric cancer were enrolled. Also, twenty healthy volunteers were enrolled as control group. All patients received gastrectomy with D2 lymphadenectomy, and surgical staging was performed. Whole blood was obtained preoperatively in all patients, and serum BMP-2 levels were quantified by commercially available ELISA kit. Immunohistochemical stain for BMP-2 in all gastric cancer tissues was performed using tissue microarray. All patients showed increased serum BMP-2 levels compared with control group, when upper normal limit was defined as the mean of control serum level + 2 × standard deviation. The mean serum BMP-2 level of lymph node positive group was significantly elevated than that of lymph node-negative group (382.7 pg/ml, 95{\%} CI 341.99-423.4 pg/ml vs 211.69 pg/ml, 95{\%} CI 191.09-232.29 pg/ml, P < 0.001). The serum BMP-2 was strongly correlated with the depth of invasion (T stage) and the extent of regional lymph node involvement (N stage) (r = 0.662, P < 0.001 and r = 0.831, P < 0.001, respectively). Moreover, the serum BMP-2 was correlated with the grade of tumor histology(r = 0.421, P = 0.008). Immunohistochemical stain showed the specific expression of BMP-2 in cancer cells compared with normal gastric mucosa. In conclusion, serum BMP-2 is associated with progression from early localized gastric cancer to locally advanced gastric cancer.",
keywords = "Bone morphogenetic protein 2, Enzyme-linked immunosorbent assay, Immunohistochemistry, Neoplasm invasiveness, Stomach neoplasm, Tumorigenesis",
author = "Yong Park and Kang, {Myoung Hee} and Seo, {Hee Yeon} and Park, {Joong Min} and Choi, {Chul Won} and Kim, {Yeul Hong} and Kim, {In Sun} and Kim, {Jun Suk} and Oh, {Sang Cheul}",
year = "2010",
month = "12",
day = "1",
doi = "10.1007/s12032-009-9358-x",
language = "English",
volume = "27",
pages = "1192--1199",
journal = "Medical oncology (Northwood, London, England)",
issn = "1357-0560",
publisher = "Humana Press",
number = "4",

}

TY - JOUR

T1 - Bone morphogenetic protein-2 levels are elevated in the patients with gastric cancer and correlate with disease progression

AU - Park, Yong

AU - Kang, Myoung Hee

AU - Seo, Hee Yeon

AU - Park, Joong Min

AU - Choi, Chul Won

AU - Kim, Yeul Hong

AU - Kim, In Sun

AU - Kim, Jun Suk

AU - Oh, Sang Cheul

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Bone morphogenetic protein-2 (BMP-2) was reported to enhance migration, invasion, and metastasis at the various types of cancer cells. The purpose of this study is to identify the role of BMP-2 in progression of gastric cancer. Forty-four patients with operable gastric cancer were enrolled. Also, twenty healthy volunteers were enrolled as control group. All patients received gastrectomy with D2 lymphadenectomy, and surgical staging was performed. Whole blood was obtained preoperatively in all patients, and serum BMP-2 levels were quantified by commercially available ELISA kit. Immunohistochemical stain for BMP-2 in all gastric cancer tissues was performed using tissue microarray. All patients showed increased serum BMP-2 levels compared with control group, when upper normal limit was defined as the mean of control serum level + 2 × standard deviation. The mean serum BMP-2 level of lymph node positive group was significantly elevated than that of lymph node-negative group (382.7 pg/ml, 95% CI 341.99-423.4 pg/ml vs 211.69 pg/ml, 95% CI 191.09-232.29 pg/ml, P < 0.001). The serum BMP-2 was strongly correlated with the depth of invasion (T stage) and the extent of regional lymph node involvement (N stage) (r = 0.662, P < 0.001 and r = 0.831, P < 0.001, respectively). Moreover, the serum BMP-2 was correlated with the grade of tumor histology(r = 0.421, P = 0.008). Immunohistochemical stain showed the specific expression of BMP-2 in cancer cells compared with normal gastric mucosa. In conclusion, serum BMP-2 is associated with progression from early localized gastric cancer to locally advanced gastric cancer.

AB - Bone morphogenetic protein-2 (BMP-2) was reported to enhance migration, invasion, and metastasis at the various types of cancer cells. The purpose of this study is to identify the role of BMP-2 in progression of gastric cancer. Forty-four patients with operable gastric cancer were enrolled. Also, twenty healthy volunteers were enrolled as control group. All patients received gastrectomy with D2 lymphadenectomy, and surgical staging was performed. Whole blood was obtained preoperatively in all patients, and serum BMP-2 levels were quantified by commercially available ELISA kit. Immunohistochemical stain for BMP-2 in all gastric cancer tissues was performed using tissue microarray. All patients showed increased serum BMP-2 levels compared with control group, when upper normal limit was defined as the mean of control serum level + 2 × standard deviation. The mean serum BMP-2 level of lymph node positive group was significantly elevated than that of lymph node-negative group (382.7 pg/ml, 95% CI 341.99-423.4 pg/ml vs 211.69 pg/ml, 95% CI 191.09-232.29 pg/ml, P < 0.001). The serum BMP-2 was strongly correlated with the depth of invasion (T stage) and the extent of regional lymph node involvement (N stage) (r = 0.662, P < 0.001 and r = 0.831, P < 0.001, respectively). Moreover, the serum BMP-2 was correlated with the grade of tumor histology(r = 0.421, P = 0.008). Immunohistochemical stain showed the specific expression of BMP-2 in cancer cells compared with normal gastric mucosa. In conclusion, serum BMP-2 is associated with progression from early localized gastric cancer to locally advanced gastric cancer.

KW - Bone morphogenetic protein 2

KW - Enzyme-linked immunosorbent assay

KW - Immunohistochemistry

KW - Neoplasm invasiveness

KW - Stomach neoplasm

KW - Tumorigenesis

UR - http://www.scopus.com/inward/record.url?scp=77954031283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954031283&partnerID=8YFLogxK

U2 - 10.1007/s12032-009-9358-x

DO - 10.1007/s12032-009-9358-x

M3 - Article

VL - 27

SP - 1192

EP - 1199

JO - Medical oncology (Northwood, London, England)

JF - Medical oncology (Northwood, London, England)

SN - 1357-0560

IS - 4

ER -